Last update 16 Jun 2026

DAT-2645

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DAT-2645
Target
PARG
Action
inhibitors
Mechanism
PARG inhibitors(Poly(ADP-ribose) glycohydrolase inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication
HRD-positive Ovarian CancerOvarian Epithelial CarcinomaLiver Cancer+ [10]
Inactive Indication-
Originator Organization
Beijing Danqing Pharmaceutical Technology Co., Ltd.
Active Organization
Beijing Danqing Pharmaceutical Technology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with DAT-2645
CTR20243912
/ RecruitingPhase 1
评估DAT-2645在携带BRCA1/2功能缺失突变和/或DNA损伤修复（DDR）通路中其他缺陷的晚期/转移性实体瘤患者中的安全性、耐受性、药代动力学、药效学和初步疗效的剂量递增、剂量扩展、开放、I期研究
[Translation] A dose-escalation, dose-expansion, open-label, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss-of-function mutations and/or other defects in the DNA damage repair (DDR) pathway
NCT06614751
/ Not yet recruitingPhase 1
A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of DAT-2645 in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DNA Damage Repair Pathway
CTR20262136
/ Not yet recruitingPhase 2
评估DAT-2645在携带BRCA1/2功能缺失突变、HRD阳性的晚期/转移性卵巢癌的疗效、安全性和药代动力学的II期研究
[Translation] A phase II study evaluating the efficacy, safety, and pharmacokinetics of DAT-2645 in advanced/metastatic ovarian cancer with BRCA1/2 loss-of-function mutations and HRD positivity.
100 Clinical Results associated with DAT-2645
Login to view more data
100 Translational Medicine associated with DAT-2645
Login to view more data
100 Patents (Medical) associated with DAT-2645
Login to view more data
100 Deals associated with DAT-2645
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HRD-positive Ovarian CancerPhase 2
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
15 Jun 2026
Ovarian Epithelial CarcinomaPhase 2
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
28 May 2026
Liver CancerPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
20 Dec 2024
Advanced cancerPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Breast CancerPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Colorectal CancerPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Endometrial CarcinomaPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Metastatic Solid TumorPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Pancreatic CancerPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Prostatic CancerPhase 1
China
Beijing Danqing Pharmaceutical Technology Co., Ltd.
01 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free